CLINICAL RESEARCH: VALVULAR HEART DISEASE
Dobutamine stress echocardiography for noninvasive assessment and risk stratification of patients with rheumatic mitral stenosis
Gilmar Reis, MD, PhD* ,*,
Mauro S. Motta, MD,
Marcia M. Barbosa, MD, PhD* ,
William A. Esteves, MD ,
Sonia F. Souza, MD and
Edimar A. Bocchi, MD, PhD||
* Cardiovascular Research Program, Pontificia Universidade Catolica de Minas Gerais, Belo Horizonte, Brazil
Cardiologica, Clinica de Diagnostico Cardiovascular, Belo Horizonte, Brazil
Ecocenter, Vera Cruz and Socor Hospitals, Belo Horizonte, Brazil
Division of Cardiology, Vera Cruz Hospital, Belo Horizonte, Brazil
|| Heart Institute–University of Sao Paulo Medical School, Sao Paulo, Brazil
Manuscript received October 11, 2002;
revised manuscript received September 17, 2003,
accepted September 26, 2003.
* Reprint requests and correspondence: Dr. Gilmar Reis, Pontificia Universidade Catolica de Minas Gerais, R. Grao Para 454, Santa Efigenia, 30150-340 Belo Horizonte–MG, Brazil.
greis{at}pucminas.br
OBJECTIVES: We sought to evaluate the impact of dobutamine stress echocardiography (DSE) in patients with known rheumatic mitral stenosis (MS) in order to assess its safety, feasibility, and prognostic correlation to well-known clinical outcomes.
BACKGROUND: Noninvasive prognostic assessment of MS still represents an unresolved task in patients with clinically challenging disease.
METHODS: Dobutamine stress echocardiography was performed in 53 patients with MS (8 males; age 37.4 ± 11.3 years) with no major complications.
RESULTS: During follow-up (60.5 ± 11.0 months), 29 patients presented with clinical events: 16 hospitalizations, seven cases of acute pulmonary edema, and six symptomatic supraventricular arrhythmias. On multivariate analysis, the diastolic mitral valve mean gradient at peak DSE (DSE-MG) was the best predictor of clinical events (p < 0.008), especially in patients with moderate disease (p < 0.001). The best performance of DSE for the detection of clinical events was obtained at a cut-off value of 18 mm Hg DSE-MG (sensitivity 90%, specificity 87%, and accuracy 90%). The addition of DSE to the conventional cardiology work-up would allow a 17% increment for the detection of high-risk patients in the entire population and a 40% increment in patients with presumed moderate disease.
CONCLUSIONS: In patients with MS, DSE is a safe and highly feasible stress test. A DSE-MG  18 mm Hg identifies a subgroup of high-risk patients in whom a more aggressive approach may be warranted; on the other hand, patients with a DSE-MG <18 mm Hg predicts an uneventful clinical course and may justify a more conservative strategy.
|
Abbreviations and Acronyms
| | AF | = atrial fibrillation | | CAD | = coronary artery disease | | DSE | = dobutamine stress echocardiography | | DSE-MG | = mean diastolic mitral valve gradient at peak dobutamine stress echocardiography | | LV | = left ventricular | | MR | = mitral regurgitation | | MS | = mitral stenosis | | MVA | = mitral valve orifice area | | NYHA | = New York Heart Association | | TR | = tricuspid regurgitation |
|
This article has been cited by other articles:
|
|
|
|
 
R. Sicari, P. Nihoyannopoulos, A. Evangelista, J. Kasprzak, P. Lancellotti, D. Poldermans, J.-U. Voigt, J. L. Zamorano, and on behalf of the European Association of Echocardi
Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC)
Eur J Echocardiogr,
July 1, 2008;
9(4):
415 - 437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Magne, M. Senechal, P. Mathieu, J. G. Dumesnil, F. Dagenais, and P. Pibarot
Restrictive Annuloplasty for Ischemic Mitral Regurgitation May Induce Functional Mitral Stenosis
J. Am. Coll. Cardiol.,
April 29, 2008;
51(17):
1692 - 1701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H. Marwick
Restrictive Annuloplasty for Ischemic Mitral Regurgitation: Too Little or Too Much?
J. Am. Coll. Cardiol.,
April 29, 2008;
51(17):
1702 - 1703.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Mittnacht, M. Fanshawe, and S. Konstadt
Anesthetic Considerations in the Patient With Valvular Heart Disease Undergoing Noncardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia,
March 1, 2008;
12(1):
33 - 59.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. A Pierard and P. Lancellotti
Stress testing in valve disease
Heart,
June 1, 2007;
93(6):
766 - 772.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Weyman
The year in echocardiography
J. Am. Coll. Cardiol.,
February 1, 2005;
45(3):
448 - 455.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, B. H. Greenberg, J. D. Knoke, K. U. Knowlton, W. Y.W. Lew, J. Narula, D. Sahn, et al.
Highlights of the year in JACC 2004
J. Am. Coll. Cardiol.,
January 4, 2005;
45(1):
137 - 153.
[Full Text]
[PDF]
|
|
|
|
